{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T22:47:49Z","timestamp":1776984469026,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Wroclaw Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This study was carried out to assess whether a prolonged time between primary transurethral resection of non-muscle-invasive bladder cancer (TURB) and implementation of bacillus Calmette\u2013Guerin (BCG) immunotherapy (time to BCG; TTBCG) is associated with adverse oncological survival in patients with T1 high-grade (HG) non-muscle-invasive bladder cancer\u00a0(NMIBC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Data on 429 patients from 13 tertiary care centers with primary T1HG NMIBC treated with reTURB and maintenance BCG between 2001 and 2019 were retrospectively reviewed. Change-point regression was applied following Muggeo\u2019s approach. The population was divided into subgroups according to TTBCG, whereas the recurrence-free survival (RFS) and progression-free survival\u00a0(PFS) were estimated with log-rank tests. Additionally, Cox regression analyses were performed. Due to differences in baseline patient characteristics, propensity-score-matched analysis (PSM) and inverse-probability weighting (IPW) were implemented.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median TTBCG was 95\u00a0days (interquartile range (IQR): 71\u2013127). The change-point regression analysis revealed a gradually increasing risk of recurrence with growing TTBCG. The risk of tumor progression gradually increased until a TTBCG of approximately 18\u00a0weeks. When the study population was divided into two subgroups (time intervals:\u2009\u2264\u2009101 and\u2009&gt;\u2009101\u00a0days), statistically significant differences were found for both RFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.029) and PFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.005). Furthermore, in patients with a viable tumor at reTURB, there were no differences in RFS and PFS. After both PSM and IPW, statistically significant differences were found for both RFS and PFS, with worse results for longer TTBCG.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study shows that delaying BCG immunotherapy after TURB of T1HG NMIBC is associated with an increased risk of tumor recurrence and progression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-020-03522-3","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T19:03:56Z","timestamp":1606158236000},"page":"2545-2552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1727-2283","authenticated-orcid":false,"given":"Wojciech","family":"Krajewski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Chorbi\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u0142awomir","family":"Poletajew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Tukiendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Afferi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy Yuen-Chun","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Muilwijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Joniau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Tafuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cianflone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Mari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ettore","family":"Di Trapani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kees","family":"Hendricksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Alvarez-Maestro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Rodr\u00edguez-Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Simone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Tully","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ko\u0142odziej","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Krajewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rados\u0142aw","family":"Piszczek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romuald","family":"Zdrojowy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"European Association of Urology\u2014Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"3522_CR1","first-page":"639","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk M, Burger M, Comperat EM et al (2019) European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u20142019 update. EurUrol 76:639\u2013657","journal-title":"EurUrol"},{"key":"3522_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fonc.2019.00121","volume":"9","author":"D Huang","year":"2019","unstructured":"Huang D, Jin YH, Weng H et al (2019) Combination of intravesicalbacille Calmette\u2013Guerin and chemotherapy vs. bacille Calmette\u2013Guerin alone in non-muscle invasive bladder cancer: a meta-analysis. Front Oncol 9:121","journal-title":"Front Oncol"},{"key":"3522_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0090-4295(98)00212-X","volume":"52","author":"JA Witjes","year":"1998","unstructured":"Witjes JA, Meijden APM, Collette L et al (1998) Long-term follow-up of an EORTC randomized prospective trial comparing intravesicalbacille Calmette\u2013Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 52:403\u2013410","journal-title":"Urology"},{"key":"3522_CR4","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E et al (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette\u2013Guerin: the CUETO scoring model. J Urol 182:2195\u20132203","journal-title":"J Urol"},{"key":"3522_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrurol.2015.58","volume":"12","author":"AM Kamat","year":"2015","unstructured":"Kamat AM, Flaig TW, Grossman HB et al (2015) Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol 12:225\u2013235","journal-title":"Nat Rev Urol"},{"key":"3522_CR6","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1002\/sim.1545","volume":"22","author":"VM Muggeo","year":"2003","unstructured":"Muggeo VM (2003) Estimating regression models with unknown break-points. Stat Med 22:3055\u20133071","journal-title":"Stat Med"},{"key":"3522_CR7","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1002\/sim.3532","volume":"28","author":"A Sjolander","year":"2009","unstructured":"Sjolander A (2009) Propensity scores and M-structures. Stat Med 28:1416\u20131420 (author reply 20-3)","journal-title":"Stat Med"},{"key":"3522_CR8","first-page":"1","volume":"20","author":"A Olmos","year":"2015","unstructured":"Olmos A, Govindasamy P (2015) A practical guide for using propensity score weighting in R. Pract Assess Res Eval 20:1\u20138","journal-title":"Pract Assess Res Eval"},{"issue":"Suppl 1","key":"3522_CR9","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1038\/bjc.2015.48","volume":"112","author":"RD Neal","year":"2015","unstructured":"Neal RD, Tharmanathan P, France B et al (2015) Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer 112(Suppl 1):S92-107","journal-title":"Br J Cancer"},{"key":"3522_CR10","unstructured":"Shiff B, Breau RH, Patel P et al (2020) Impact of time-to-surgery and surgical delay on oncologic outcomes for renal cell carcinoma. J Urol. 101097JU0000000000001230"},{"key":"3522_CR11","doi-asserted-by":"publisher","first-page":"e56327","DOI":"10.1371\/journal.pone.0056327","volume":"8","author":"CA Rentsch","year":"2013","unstructured":"Rentsch CA, Biot C, Gsponer JR et al (2013) BCG-mediated bladder cancer immunotherapy: identifying determinants of treatment response using a calibrated mathematical model. PLoS ONE 8:e56327","journal-title":"PLoS ONE"},{"key":"3522_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1464-410X.2012.11391.x","volume":"112","author":"IA Sternberg","year":"2013","unstructured":"Sternberg IA, Keren Paz GE, Chen LY, Herr HW, Dalbagni G (2013) Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection. BJU Int 112:54\u201359","journal-title":"BJU Int"},{"key":"3522_CR13","first-page":"1124","volume":"96","author":"JC Chen","year":"2016","unstructured":"Chen JC, Li T, Ning XH et al (2016) Clinical significance of residual tumors at repeat transurethral resection in patients with T1 bladder cancer. Zhonghua Yi XueZaZhi 96:1124\u20131127","journal-title":"Zhonghua Yi XueZaZhi"},{"issue":"1","key":"3522_CR14","first-page":"e950","volume":"18","author":"MO Grimm","year":"2020","unstructured":"Grimm MO, van der Heijden AG, Colombel M et al (2020) Treatment of high-grade non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the european association of urology research foundation randomised phase III clinical trial \u201cNIMBUS.\u201d EurUrol 18(1):e950","journal-title":"EurUrol"},{"key":"3522_CR15","first-page":"60","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier S, Sylvester RJ, Collette L et al (2016) EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette\u2013Guerin. EurUrol 69:60\u201369","journal-title":"EurUrol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03522-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-020-03522-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03522-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T16:19:47Z","timestamp":1628007587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-020-03522-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["3522"],"URL":"https:\/\/doi.org\/10.1007\/s00345-020-03522-3","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"assertion":[{"value":"20 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}